Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1993;94(2):91-102.
doi: 10.1007/BF01245003.

Naturally-occurring isoquinolines perturb monamine metabolism in the brain: studied by in vivo microdialysis

Affiliations

Naturally-occurring isoquinolines perturb monamine metabolism in the brain: studied by in vivo microdialysis

W Maruyama et al. J Neural Transm Gen Sect. 1993.

Abstract

Naturally occurring isoquinolines affected the monoamine metabolism in the rat striatum, as proved by in vivo microdialysis technique. By analysis of monoamines and their metabolites in the dialysate, dopamine-derived 6,7-dihydroxy-1,2,3,4-tetrahydroisoquinolines were found to inhibit monoamine oxidase and catechol-O-methyltransferase activity. 1-Methyl- and 2-methyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline were found to inhibit activity of type A monoamine oxidase most markedly. To compare the structure-activity relationship, corresponding isoquinolines without a catechol structure were also examined. The inhibition by catechol isoquinolines was more manifest than those without a catechol structure. Among latter isoquinolines, N-methyl-isoquinolinium ion was the most potent inhibitor of monoamine oxidase. In addition, catechol isoquinolines increased monoamine levels in the brain. The number and the site of the methyl group are essentially required for the inhibition of monoamine oxidase and a catechol structure for that of catechol-O-methyl-transferase. These results are discussed in relation to possible involvement of these isoquinolines to the clinical features of some neuro-psychiatric diseases, such as alcoholism or in L-DOPA therapy.

PubMed Disclaimer

Similar articles

Cited by

References

    1. J Neurochem. 1990 Sep;55(3):981-8 - PubMed
    1. Biochem Biophys Res Commun. 1991 Jun 14;177(2):603-9 - PubMed
    1. J Neurochem. 1986 Apr;46(4):1277-82 - PubMed
    1. J Neurochem. 1992 Aug;59(2):395-400 - PubMed
    1. J Neural Transm Park Dis Dement Sect. 1989;1(4):269-78 - PubMed

Publication types

MeSH terms